C. Lowell Parsons

Founder at Vaneltix Pharma, Inc.

78 year

Health Technology

Consumer Services

Profile

C.
Lowell Parsons is the founder of Vaneltix Pharma, Inc. which was founded in 1997.
He holds the title of Co-Chairman & President at Vaneltix Pharma, Inc. Dr. Parsons's current job is as a Professor at the University of California San Diego, where he starts in 1988.
Dr. Parsons's former job was as a Director at Valentis, Inc. Dr. Parsons obtained a doctorate degree from Yale School of Medicine in 1970.

C. Lowell Parsons active positions

Companies	Position	Start
Vaneltix Pharma, Inc. Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ.	Founder	1996-12-31
University of California San Diego	Corporate Officer/Principal	2011-10-27

All active positions of C. Lowell Parsons

Former positions of C. Lowell Parsons

Companies	Position	End
Valentis, Inc. Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.	Director/Board Member	2007-07-30

See the detail of C. Lowell Parsons's experience

Training of C. Lowell Parsons

Yale School of Medicine

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of C. Lowell Parsons's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Valentis, Inc. Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.	Health Technology
Vaneltix Pharma, Inc. Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ.	Health Technology